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Abstract 
 
Background/Aim. Survivin is a multifunctional protein 
abundantly expressed in tumors of various types, including 
melanoma. There are still sparse data regarding relationship 
of melanoma cell survivin expression with accepted histopa-
thological characteristics as well as serum concentration.   
The aim of this study was to investigate the association of 
local tumor survivin expression (primary tumor and metas-
tatic lesions) and serum concentration with clinical and his-
topathological parameters in melanoma patients. Methods. 
The level of survivin expression was determined immunocy-
tochemically in tumor tissue and with ELISA test in the se-
rum of 84 melanoma patients diagnosed from 2009 to 2013 
at the Institute for Pathology and Forensic Medicine and 
Institute for Medical Research at Military Medical Academy, 
Belgrade, Serbia. Results. The intensity of survivin expres-
sion was significantly higher in the patients whose tumor 
had ulceration, higher mitotic index, higher Clark and Bres-
low stage, that made vascular invasion or spread through 
lymphatic vessels in primary tumor, and was significantly 
higher in the patients with metastatic disease. Survivin ex-
pression and the number of survivin positive cells in metas-
tatic lesions were significantly associated with the duration 
of disease free interval (DFI). The patients with high ex-
pression score had almost double shorter DFI comparing to 
those with weak local survivin expression and a small num-
ber of survivin+ cells (9 ± 7 vs 19 ± 13 months, respec-
tively). The degree of tumor infiltrating lymphocytes pres-
ence in tumor tissue was significantly associated with serum 
survivin concentration, with lowest average level detected in 
samples of patients with the highest degree of infiltration. 
Serum survivin concentrations were highest in samples of 
melanoma patients with IA American Joint Commission on 
Cancer (AJCC) clinical stage, pT1a histological stage, pa-
tients whose tumors were still in horizontal growth phase, 
without signs of lympho-hematological disease spreading, 
with the highest number of mitoses and the smallest Clark 
index. Conclusion. Survivin expression in tumor tissue and 
its serum concetration significantly correlate with clinical 
and histopathological parameters. Serum levels could be 
important in initial follow-up as indicators of  those patients 
that would have aggressive local tumor growth and spread-
ing. Survivin determination in tumor tissue is of great sig-
nificance in estimation of DFI. 
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Uvod/Cilj. Survivin je multifunkcionalni protein bogato is-
poljen u tumorima različite vrste, uključujući i melanom. Re-
tki su radovi koji opisuju odnos ispoljavanja survivina u me-
lanomskim ćelijama sa njegovom serumskom koncentraci-
jom kao i sa histopatološkim karakteristikama melanoma. 
Cilj rada bio je da se ispita udruženost lokalne ekspresije 
survivina u tumoru (primarni tumor i metastatske promene) 
i serumske koncentracije sa kliničkim i histopatološkim pa-
rametrima kod bolesnika sa melanomom. Metode. Nivo 
ekspresije survivina određivan je imunocitohistohemijski u 
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tumorskom tkivu i ELISA testom u serumu 84 bolesnika sa 
melanomom, dijagnostikovanih u periodu od 2009. do 2013. 
na Institutu za patologiju i sudsku medicinu i Institutu za 
medicinska istraživanja na Vojnomedicinskoj akademiji, Be-
ograd, Srbija. Rezultati. Intezitet ekspresije survivina bio je 
značajno veći kod bolesnika čiji su tumori bili ulcerisani, sa 
visokim mitotskim indeksom, visokim Clark i Breslow inde-
ksom, sa prisutnom vaskularnom i limfnom invazijom, kao i 
kod onih sa metastatskom bolesti. Ispoljavanje survivina i 
broj survivin pozitivnih ćelija u metastatskim lezijama bio je 
značajno udružen sa trajanjem intervala bez bolesti (disease 
free interval – DFI). Bolesnici sa visokim skorom ekspresije 
imali su skoro dvostruko kraći DFI u odnosu na one sa sla-
bom lokalnom ekspresijom survivina i malim brojem survi-
vin pozitivnih ćelija (9 ± 7 vs 19 ± 13 meseci). Stepen prisu-
stva tumor infiltrišućih limfocita u tumorskom tkivu bio je 
značajno udružen sa koncetracijom survivina u serumu, sa 
najnižim prosečnim vrednostima detektovanim u uzorcima 
bolesnika sa najvećim stepenom infiltracije. Serumske kon-
centracije survivina bile su najveće u uzorcima bolesnika sa 
melanomom IA kliničkog stadijuma American Joint Commissi-
on on Cancer (AJCC), pT1a histološkog stadijuma, bolesnika 
čiji su tumori bili u horizontalnoj fazi rasta, bez znakova ši-
renja limfohematogenim putem, sa najvećim brojem mitoza 
i koji su imali najmanji Clark indeks. Zaključak. Ekspresija 
survivina u tumorskom tkivu i njegova serumska koncentra-
cija značajno korelišu sa kliničkim i histopatološkim para-
metrima melanoma. Serumski nivo može biti važan kao ini-
cijalni indikator kod onih bolesnika koji bi mogli imati agre-
sivan lokalni tumorski rast i širenje. Određivanje survivina u 
tumorskom tkivu, kako u primarnom tumoru tako i u meta-
stazama, od velikog je značaja u utvrđivanju trajanja DFI. 
 
Ključne reči:  
proteini, onkogeni; biološki pokazatelji; melanom; his-
tologija; imunohistohemija; osetljivost i specifičnost. 
 
Introduction 
Melanoma is the deadliest form of skin cancer. It is reco-
gnized that in humans, the malignant transformation of normal 
melanocytes into melanoma cells is due to specific genetic 
predisposition and the influence of environmental factors 1. 
Recent studies of the role of survivin in the pathogenesis of 
malignant tumors were extensive and primarily directed into 
its role as a biomarker. The latest publications suggest that 
survivin might have an important role in melanomas.  
Survivin is a multifunctional protein with an important 
role in the inhibition of apoptosis, regulation of mitotic activity 
and angiogenesis. External and intrinsic pathways of apoptotic 
signals are interrelated at the levels of effector enzymes called 
caspases. Caspases 3 and 7 are targets for suppression by a 
family of endogenous inhibitors of apoptotic proteins (IAPs) 
that in humans is composed of 8 proteins such as X-IAP, cI-
AP1, cIAP2, ML-IAP (Livin; K-IAP), Naip, ILP2 (TS-IAP), 
Apollon/Bruce  and survivin) 2. Survivin is the inhibitor of 
apoptosis through its effect on various caspases, through bin-
ding and inhibition of mitochondrial protein SMAC/Diablo 
and stabilization of XIAP proteins by blockade of 
ubiquitination and degradation of proteasome activity. 
Under normal physiological conditions, expression of 
survivin is regulated by the cell cycle and connected to the 
G2M phase.  Survivin is a part of mitotic spindle in connection 
with tubulin and is important regulator of mitosis. Malignant 
tumor cells and human fetal cells have increased expression of 
survivin while it is absent in the mature and well-differentiated 
human tissues. The results of the most recent investigations 
show that survivin correlates well with progression and with 
outcome of various types of solid tumors and hematological 
malignancies. It has been shown that high concentrations of 
survivin in malignant tumors induce resistance of tumor cells 
on chemotherapy and ionizing radiation. 
Immunocytochemical studies show that increased 
expression of survivin is not just a sign of increased mitotic 
rate in tumor but that its increase is independent from tumor 
mitotic rate 3. Furthermore, in the vast majority of tumors, 
survivin is increased not only during cell mitosis but in all 
phases of the cell cycle 4–6. Out of many acquired genetic al-
terations in melanoma cells, the best described are mutations 
of BRAF, HRAS or NRAS, increased telomerase activity, as 
well as defects in signaling cascade and retinoblastoma gene 
and p53 1, 4. Although the mechanisms responsible for incre-
ased expression of survivin in the transformation of normal 
melanocytes into malignant melanoma cells are unknown, 
the epigenetic, genetic and post-translational mechanisms for 
regulation of survivin gene are described in other types of 
cells. The role of survivin in cancerogenesis is not limited 
only on the inhibition of apoptosis and subsequently chemo-
resistance of malignant cells but survivin is also important 
for neoangiogenesis. 
In the animal model of melanoma it has been shown 
that expression of survivin is increased in melanoma cells 
in comparison with normal melanocytes and that survivin is 
necessary for viability of melanoma cells and that in these 
animals exposure of melanocytes to UV light leads into 
malignant transformation of melanoma cells and their me-
tastatic potential 3. 
Increased expression of survivin has been demonstrated 
in invasive and metastatic melanoma and it is believed that 
this is the consequence of dysregulation of apoptosis, mitosis 
and angiogenesis 3. DNA microarray analysis has shown that 
survivin gene is one out of four most important genes with 
increased expression in melanoma. Immunocytochemical 
studies performed on melanocytic lesions and melanoma ca-
ses show different results in survivin expression in relation to 
the phase of this malignant disease and variation of survival 
localization in different cell compartments such as 
cytoplasm, nucleus or in both, nucleus and cytoplasm 
simultaneously 5–7. 
The aim of this study was to assess the values of locali-
zed and systemic expression of survivin in melanoma pati-
ents as well as the correlation between expression of survivin 
and disease progression and histopathological parameters 
[clinical stage, histological stage, growth phase, mitotic rate 
of the tumor, tumor infiltrating lymphocytes (TIL), Clark’s 
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Table 1 





Mitoses Clark Breslow Ulceration Vascular 
invasion 
Spreading Patients 
IA 1.1 ± 1.5 pT1a 1.1 ± 1.4 0 1.6 ± 1.1 I  nd < 1 1.3 ± 1.3 -  1.6 ± 1.1 - 1.7 ± 1.0 none 1.5 ± 1.0 CN 0.3±0.5 
IB 1.6 ± 1.1 pT1b 1.8 ± 1.0 1 1.9 ± 0.8 II 1.0 ± 1.0 2 1.6 ± 1.1 + 2.1 ± 0.8 + 2.2 ± 0.8 L 2.0 ± 1.0 DN 0.4±0.5 
IIA 1.3 ± 0.5 pT2a  1.5 ± 1.2 2 1.3 ± 1.2 III 1.5 ± 1.0 3 1.4 ± 0.6   L+H 1.6 ± 1.0 MP 2.2±1.0 
IIB 1.6 ± 0.6 pT2b 1.0 ± 0.8 3 2.5 ± 0.6 IV 1.9 ± 1.0 4 1.7 ± 0.8     
IIC 1.8 ± 0.9 pT3a 1.3 ± 0.5 4 2.5 ± 1.0 V 2.0 ± 0.9 5 2.4 ± 0.5     
IIIA 2.0 ± 0.9 pT3b 1.5 ± 0.6 6 1.0 ± 0.7   5 1.9 ± 0.9     
IIIB 2.0 ± 0.8 pT4a 2.4 ± 0.7 > 6 2.3 ± 0.5       
IIIC 2.2 ± 0.7 pT4b 2.2 ± 0.8        
IV  1.8 ± 0.8         
 IA /IIB * pT1a  /pT4a * 3  / > 6 * II /IV * < 1  5 * -  /+ * -  /+ * none  /L * CN  /MP *** 
 IIA /IIIA * pT1a /pT4b * 6  / > 6 * II  /V ** 3  5 **    DN  /MP *** 
IIA /IIIC * pT2b /pT4a *        
level, Breslow’s thickness, tumor ulceration, histological 
subtype and tumor regression]. 
Methods 
The tumor survivin expression was determined 
immunohistochemically in tissue samples of 84 patients, 48 
male, 36 female, aged from 25 to 78 years, diagnosed in the 
Institute for Pathology and Forensic Medicine, Military Me-
dical Academy (MMA), Belgrade, Serbia in a time interval 
from 2009 to 2013. Serum survivin concentration was de-
termined by commercial ELISA (R&D Systems, USA) in 
samples of the same patients, at the Institute for Medical Re-
search, MMA, Belgrade, Serbia.  
The level of survivin expression was determined 
immunocytochemically in tumor tissue and with ELISA test 
in the serum of 84 melanoma patients of which 48 were male 
and 36 female, aged from 25 to 78 years, diagnosed at the In-
stitute for Pathology and Forensic Medicine of the MMA, 
Belgrade, Serbia. All the patients were stratified according to 
the American Joint Commission on Cancer (AJCC) clinical 
stage in the following groups: stage I 23 patients, stage II 17 
patients, stage III 28 patients and stage IV 12 patients. The 
control group was composed of 20 patients with dysplastic 
and 20 patients with classic naevi; for testing of survivin le-
vel in the serum, control group was composed of 20 healthy 
persons without melanoma. 
 pT2b  /pT4b *        
 pT3a  /pT4a *        
 pT3b  /pT4b *        
Spreading (L – lymphatic, L+H – lympho-hematological); Patients (CN – control naevus, DN – dysplastic naevus, MP – mela-
noma patients); (* p < 0.05, ** p < 0.01, ***p < 0.0001, Mann Whitney test). 
 
Tissue samples from patients’ melanomas were fixed in 
4% buffered formalin, dehydrated, cleared in xylen and pa-
raffin impregnated in a Leica ASP300 tissue processor, and 
paraffin embedded tissue was sliced in 4µ thin tissue secti-
ons. The DAKO anti-survivin mouse monoclonal primary 
antibody 1:100 was used after microwave antigen retrieval in 
the DAKO retrieval solution pH 6.0. The CSA II DAKO la-
belling system was also used. DAKO mouse anti IgG2a 
antibody was used for negative control in the same 1:100 di-
lution as the primary antibody. The intensity of staining for 
survivin was determined using the semi-quantitative method 
as follows: 0 for no staining, 1+ for weak staining, 2+ for 
moderate staining and 3+ for strong staining and according 
to the percentage of positive tumor cells results were evalua-
ted as: 0 – ( od 5%); 1 – (5–25%); 2 – (25–50%); 3 – (50–
75%) i 4 – (> 75%)  8.  
Blood samples were left to completely coagulate, serum 
samples were centrifuged (1000  g) for 15 min and stored at 
-70°C until tested for human survivin using Human Survivin 
Immunoassay, R&D ELISA Quantikine USA, cat. no. 
DSV00.  
Statistical analysis of our data was performed with 
GraphPad Prism software using ANOVA test (with Bonfer-
roni post testing), Mann-Whitney test and Wilcoxon test.   
Results 
Tumor tissue samples from melanoma patients showed 
a significantly higher average survivin expression in compa-
rison with the samples of dysplastic naevi and benign 
melanocytic lesions of the control group (p < 0.0001) (Table 
1). Analysis of survivin tissue expression in patients samples 
according to the AJCC clinical staging showed that even the 
patients with stage Ia had significant local tumor production. 
Comparison of survivin expression between the patients with 
different clinical stages showed the lowest values in stage IA 
and highest in stages IIIA and IIIC (Table 1). Survivin tissue 
expression in the melanoma patients stage IIA was 
statistically lower than in tumor tissue in the patients in sta-
ges IIIA i IIIC (p = 0.0371; p = 0.0428). We found a gradua-
te and constant increase of survivin tissue expression level 
following the disease progression reflected in advancing cli-
nical stages. The correlation of values of survivin tissue 
expression with histological stage of melanoma showed si-
milar results. The lowest average values of survivin 
expression score were detected in the samples of tumor tis-
sue from the patients with pT1a stage, significantly lower 
than values found in the patients stage pT4a (p = 0.0486) and 
pT4b (p = 0.0286), that had the highest expression of survi-
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vin in tumor cells (Table 1). Average survivin expression 
score in the melanoma tissue of the patients in pT4a and 
pT4b was significantly higher comparing to the patients in 
stage pT2a (p = 0.0276; p = 0.0256) and pT3a (p = 0.0321; p 
= 0.0418). Comparing expression of survivin in melanoma 
tissue with the Clark levels we found that the intensity of 
survivin expression in Clark level II was significantly lower 
than in Clark level IV and V (p = 0.0180; p = 0.0102) (Table 
1). Analysis according to the Breslow score showed similar 
findings with the highest average values of survivin found in 
the tissue samples of the patients with the Breslow thickness 
4–5mm and lowest in the patients with the Breslow thickness 
< 1 mm. The patients with the highest Breslow score had 
significantly higher survivin tissue expression in their tumors 
comparing to the patients that had Breslow less than 1 mm (p 
= 0.0353) and the patients that had Breslow 2–3 mm thick 
melanomas (p = 0.0087) (Table 1). Ulcerated melanomas 
showed increased survivin expression comparing to non ul-
cerated ones (p = 0.0476) (Table 1). The intensity of 
expression of survivin was statistically significantly higher in 
melanomas with the highest mitotic activity (> 6 mitosis per 
mm2) than in melanomas with 3 mitosis (p = 0.0334) and 
melanomas with 6 mitoses (p = 0.0371) (Table 1). We found 
the highest values of survivin expression in melanomas 
without intratumoral lymphocytic infiltration (TIL) and the 
lowest values in melanomas with the brisk tumor infiltrating 
lymphocytes (TILs). This difference was not significant.  
There was no significant difference between the intensity 
of survivin staining and vertical or horizontal phases of mela-
noma growth, histological type of tumor and the presence or 
the absence of tumor regression. Positive immunohistochemi-
cal staining to survivin in tumor cells of primary and metasta-
tic melanoma is shown in Figures 1a and b. 
Analysis of survivin expression and the number of survi-
vin positive cells in metastatic lesions of stage IV patients 
showed a significant association with the duration of disease 
free interval (DFI) (Figure 2). The patients with high 
expression score had almost double shorter DFI comparing to 
those with weak local survivin expression and a small number 





Fig. 1 – Survivin positive tumor cells in primary melanoma (a), and metastatic melanoma (b) (survivin  




Fig. 2 – Association of disease free interval (DFI) duration with intensity of survivin expression and the number of sur-
vivin positive cells in metastatic melanoma lesions. A – Survivin expression in metastatic tumor lesions according to DFI 
duration; B – Number of survivin positive tumor cells in metastatic lesions according to DFI duration;  
(ґ ± SD, intensity score, *p < 0.05, ** p < 0.01, Mann Whitney test). 
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Fig. 3 – Survivin serum concentration (ґ ± SD ng/mL) in melanoma patients samples. A – clinical stage of melanoma patients 
(AJCC); B – histological grade of primary tumor; C – tumor infiltration (lymphocytes degree in primary tumor); D – number 
of mitoses estimated in tumor cells; E – phase of primary tumor growth; F – Clark score; G – anatomic localization of pri-
mary tumor; H – direction of melanoma spread. 
 
The average survivin serum concentration was 
significantly increased in melanoma patient samples compa-
ring to samples of examinants with dysplastic naevi, benign 
pigmented skin shanges and control healthy persons. 
Analysis of survivin concentration according to clinical sta-
ges showed that the patients in IA stage had the highest ave-
rage value, significantly higher than the patients in stage IB 
(p = 0.0363) (Figure 3A). The melanoma patients in IIIC cli-
nical stage had the lowest average survivin concentration, 
significantly lower comparing to the patients of IA (p = 
0.0495), IIB (p = 0.0286) and IIIA stage (p = 0.0286). Histo-
logical staging of primary tumors showed that the patients 
with pT1a stage had the highest average serum survivin va-
lues, similarly to data found when the patients where classi-
fied according to the AJCC staging system. The patients with 
melanomas classified as pT2b had the lowest average survi-
vin concentration, significantly less than those patients 
whose tumors were pT1a (p = 0.0424), pT1b (p = 0.0294), 
pT3b (p = 0.0286), pT4a (p = 0.0159) and pT4b (p = 0.0120) 
(Figure 3B). Lymphocyte infiltration of primary tumor was 
significantly associated with survivin concentration. The pa-
tients with the highest degree of tumor infiltration by 
lymphocytes had a significantly decreased average survivin 
level comparing to the patients with no detectable infiltrating 
lymphocytes (p = 0.0114), or with mild (p = 0.0098) or mo-
derate (p = 0.0036) degree of infiltration (Figure 3C). The 
highest survivin concentration was detected in samples of the 
patients with tumor with the highest mitotic activity, 
significantly higher comparing to the patients with 1 mito-
sis/mm3 of tissue (p = 0.0276) (Figure 3D). The patients in 
horizontal growth tumor phase had significantly more survi-
vin values than those in vertical growth phase (p = 0.0211) 
(Figure 3E). Aggressive melanoma spreading according to 
Clark level was associated with lower survivin serum con-
centration. The patients with melanomas qualified as Clark II 
had a significantly increased survivin concentration compa-
ring to those with Clark IV (p = 0.0290) or Clark V (p = 
0.0285) tumors (Figure 3F). Anatomical localization of 
primary tumor was significantly associated with survivin 
concentration (Figure 3G). The patients with melanoma loca-
lized at the foot had a significantly decreased survivin con-
centration comparing to the patients with melanoma locali-
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zed at the head (p = 0.0276). Finally, the type of spreading 
was significantly related to serum survivin values. The pati-
ents without histological evidence of tumor spreading thro-
ugh lymphatic or blood vessels had a significantly increased 
average survivin concentration comparing to the patients 
with lympho and/or hematological spread tumor (p = 0.0431) 
(Figure 3H). 
Survivin concentration did not differ significantly in 
the patients with different histological type of tumor with 
different Breslow score, the presence or the absence of tu-
mor regression, ulceration or metastases. Also, survivin 
concentration did not differ significantly in the patients that 
had stable disease or clinical progression, and the patients 
who survived or died. 
Finally, when we analyzed survivin expression vs se-
rum concentration of the same patient, we found that the pa-
tients with lowest intensity of tissue expression had a 
significantly higher serum level than those with intensive lo-
cal tissue expression (p = 0.0153) and also that the patients 
with the smallest number of survivin+ cells had the highest 
value of survivin serum concentration (Figures 4A and B). 
 
 
Fig. 4 – Survivin serum concentration (ґ ± SD ng/mL) in relation to 
survivin expression in tumor tissue. A – аverage survivin serum 
concentration according to the degree of survivin expression in pri-
mary tumor tissue; B – average survivin serum concentration  
according to the degree of survivin positive tumor cells.  
(Mann Whitney test). 
Discussion 
Survivin is the only member of IAP family that is able 
to interact with the mitotic apparatus and has several functi-
ons, serving as mitotic regulator, cell death inhibitor and a 
regulator of cell migration/metastasis 9, 10. It has been propo-
sed that multiple function of survivin are associated with its 
structure modifications and distinct localization in different 
cell compartments. Nuclear localization seems to represent 
survivin potential to control the cell cycle, while 
cytoplasm/mitochondrial localization are associated with in-
hibition of the programmed cell death process 11. Therefore, 
survivin performs both, cycle-dependent and non-cycle-
dependent functions, important in response to hematopoietic 
and vascular remodeling cytokines. Additionally, there is a 
mode that cell use to transport survivin inside out, which is 
stress-induced and executed by exosome extracellular relea-
se. This extracellular survivin retains both antiapoptotic and 
proliferative functions 12–14.  
Both clinical and experimental data showed  survivin is 
excessively expressed in human melanoma samples 15, ma-
king it the important initial factor for melanoma growth 16, 
having significant influence on melanoma cell migratory po-
tential 17. Finally, comprehensive bioinformatic analysis of 
immunohistochemical and gene array studies of expressed 
genes and proteins, in order to define melanoma prognosis 
biomarkers, selected proliferating cell nuclear antigen 
(PCNA) and survivin among 254 others as priorities for furt-
her melanoma biomarkers examination 18. 
Our results showed that detectability and average score 
of survivin expression were lowest in the patients in IA 
AJCC stage, constantly increasing towards advanced disease 
stages, with a significantly highest value in the patients that 
were in stages IIIA and IIIC. These findings are consistent 
with several other studies. Piras et al. 19 showed  that survivin 
detection increase in melanoma samples with disease pro-
gression from 67% in initial stage I to over 90% in patients 
in stage II. Survivin expression was mainly localized to nuc-
lear compartment and that nuclear expression was 
significantly associated with melanoma thickness. Samples 
from primary melanomas of our patients showed 
predominantly nuclear localization (> 91%), with weak 
cytoplasmic staining. Analysis of metastatic lesions showed 
increment of cytoplasmic localization of survivin from 9% to 
25%, comparing to primary tumors of the same persons, 
which implicate different regulation of local survivin produc-
tion, at least in some melanoma metastases.  
Survivin expression in metastatic lesions from stage IV 
melanoma patients documented both by immunohistochemistry 
(IHC) and mRNA level was significantly associated with survi-
val 20. Although stage IV melanoma patients represent a very in-
homogeneous population respective to their disease progression 
and more important, to response to adjuvant therapy, mRNA 
survivin was detected in almost all (98%) of samples. But there 
was a significant distinction between numbers of survivin mR-
NA copies in metastatic lesions. These melanoma patients 
whose lesions had low survivin mRNA load showed double 
longer median survival interval than those with high number of 
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survivin mRNA copy number (24 vs 11 months). Immunohisto-
chemical findings correlated well with molecular data, characte-
rized by intense survivin staining in tumors with high mRNA 
survivin load and vice versa. There was no significant correlati-
on between clinicopathology factors and survivin mRNA copy 
number of tumors from 63 patients. 
In the group of the stage IV patients the differences of 
survivin expression in metastatic lesions were not significantly 
associated with the differences in survival interval. But, the 
intensity of survivin expression and the number of survivin 
positive cells in metastatic lesions were significantly associa-
ted with DFI. The patients with a high expression score had 
almost double shorter DFI comparing to those with weak local 
survivin expression and a small number of survivin+ melano-
ma cells (9 ± 7 vs 19 ± 13 months).  
Analysis of survivin expression according to histologi-
cal grade showed similar results as seen in different clinical 
stages. In 50% of our patients with pT1a stage survivin was 
absent and other half had weak local expression detected in a 
small number of tumor cells. Contrary, all the patients with 
pT4a and pT4b tumors had strong local expression in nume-
rous tumor cells, significantly higher than other histological 
stages. A significant correlation of survivin expression with 
histologic grade and stage was reported not only in melano-
ma 21 but also in tumor samples of the patients with endomet-
rial carcinoma 22, ovarian carcinoma 23, hepatocellular carci-
noma 24 and breast cancer 25, 26.  
The intensity of survivin expression was significantly hig-
her in the patients whose tumor had ulceration, higher mitotic 
index, higher Clark and Breslow stage, that made vascular inva-
sion or spread through lymphatic vessels in primary tumor, and 
was significantly higher in the patients with metastatic disease. 
Local survivin expression in tumor tissue was directly associa-
ted with the presence of ulceration, at least in experimental con-
dition 27, which was explained by the mutually exclusive mec-
hanism which regulates expression of caspase 3 and survivin. 
Takeushi et al. 20 showed that high level of survivin expression 
in metastatic melanoma lesions were associated with shorter 
median survival interval. 
The presence of TIL is considered as independent prog-
nostic factor for melanoma patients. It is reasonable to assu-
me that some TIL is specific for survivin overexpression in 
tumor tissue. There are several lines of evidence supporting 
this viewpoint. Patients suffering from cancers of different 
origin frequently show spontaneous anti-survivin response 
mediated by specific T lymphocytes 28, 29. In a study on TIL 
of melanoma patients, Hadrup et al. 30 identified CD8+107a+ 
cytotoxic lymphocytes specific for MAGE 1,3,4 NY-ESO-1 
antigens. Although strong in tumor expression of survivin, 
they failed to demonstrate survivin specific T cells. But, 
when they monitored specific response in a melanoma pati-
ent with long term complete remission after interleukin (IL-
2) therapy, they identified population of T lymphocytes spe-
cific for survivin (HLA-A11 restricted) 31. These T 
lymphocytes were detectable during remission period, 7 
years. Ellebaek et al. 32 further confirmed that TIL from me-
lanoma patients contain significant distinct populations of 
CD8+ CD107a+ cells that were cytotoxic to autologous tar-
get cells expressing survivin (SUR53-62) in context of HLA-
A3+/A11+, and also showed significant potential to lyse au-
tologous tumor cells 32–34. We did not find any significant 
difference in tumor tissue survivin expression whether there 
was no infiltrating lymphocytes or most intensive 
lymphocyte infiltration. But, the degree of TIL presence in 
tumor tissue was significantly associated with serum survivin 
concentration, with lowest average level detected in samples 
of patients with the highest degree of infiltration. 
Serum survivin concentrations were highest in samples 
of melanoma patients with IA AJCC clinical stage, pT1a his-
tological stage, patients whose tumors were still in horizontal 
growth phase, without signs of lymphoid hematopoietic dise-
ase spreading, with the highest number of mitoses and that 
had the smallest Clark index. All these indicate that melano-
ma in the initial phase have abundant local survivin produc-
tion, underlying the importance of exosome survivin compar-
tment at the disease beginning. Experimental data showed 
that extracellular survivin is essential in stimulating mela-
noma cell motility through upregulation of α5 integrin func-
tion 35, implicating that significant survivin production could 
enable early melanoma cells spread, both local and systemic. 
In a study on serum anti-apoptotic markers Tas et al. 36 
investigated survivin and BCL2 concentration in serum sam-
ples of 45 melanoma patients. They did not find any signifi-
cant difference in survivin values between control subjects 
and patients, nor between patients according to standard pro-
gnostic parameters. But they did find a significantly higher 
survivin concentration in patients that had lymph node invol-
vement and in patients that had metastatic disease and 
underwent dacarbazine (DTIC)-based chemotherapy. 
Contrary, in patients with early stage breast cancer survivin 
concentration significantly correlated with Ki67 and p53 
concentration, histological and nuclear grade of tumor 37.  
Finally, when we analyzed survivin expression vs serum 
concentration of the same patients, we found that the patients 
with the lowest intensity of tissue expression and the smallest 
number of survivin+ cells had significantly higher serum level 
than those with intensive local tissue expression. Those diffe-
rences could be addressed to methods sensitivity, with s 100 
EIA kit being more sensitive than immunohistochemistry. But, 
again, these findings underline that even smallest melanoma le-
sion, without signs of local survivin expression had significant 
capacity to secrete survivin, probably in exosome form, and to 
mediate all tumor biological functions that are important for fur-
ther growth and disease spreading. 
Conclusion 
According to the obtained results we could conclude 
that local survivin expression in tumor tissue (primary tumor, 
metastatic tissue) and its serum concentration significantly 
correlate with clinical and histopathological parameters of 
melanoma. Serum levels could be important in initial follow 
up as indicators of those patients that would have aggressive 
local tumor growth and spreading. Survivin determination in 
tumor tissue, both in primary tumors and metastases, is of 
great significance in estimation of disease free interval. 
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